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Abstract
Patients with rheumatoid arthritis (RA) are at higher risk to suffer from morbidity due to vaccine-preventable 
diseases and, thus, display an important target population to receive vaccines for protection from infectious 
complications. There have been only a few studies focusing on the administration of vaccines in RA patients with 
immunotherapy. Overall, antibody response rates against influenza or pneumococcal disease appeared to be only 
slightly lower than expected in healthy individuals. 
Crucial problems in the interpretation of data from studies in RA patients vaccinated against influenza and 
pneumococcal disease are the impaired comparability of studies due to different study designs and type of vaccines 
used, different health states among RA patients, heterogeneity in treatments including concomitant therapy with 
conventional DMARDs and glucocorticoids in addition to biological agents.
Assessment of vaccination status should be performed in the initial work-up of patients with RA and should 
ideally be administered before initiation of immunotherapies or during stable disease. Due to differences in antibody 
responses and uncertainty regarding maintenance of protective antibodies, routine controls for antibody titers and 
specific strategies for earlier re-vaccination might be scheduled for patients with RA.
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Introduction
Patients with rheumatoid arthritis (RA) are at high risk of 
developing infections, which may be due to the immunomodulatory 
effect of the disease itself and to the immunosuppressive effects of 
glucocorticoids, disease-modifying anti-rheumatic drugs (DMARDs) 
(e.g. methotrexate) and immunotherapies with biologic drugs, such 
as therapy targeted against tumor-necrosis-factor-alpha (TNF-α) and 
interleukin-6 (IL-6) or against B cells using anti-CD20 antibodies [1-
5]. The use of glucocorticoids, concomitant DMARD treatment during 
anti-TNF-α therapy, advanced age at the start of anti-TNF-α therapy 
and the use of infliximab or adalimumab rather than etanercept were 
strong predictors of infection [5].
Influenza and pneumococcoal infections are two vaccine-
preventable infectious diseases which have been associated with high 
morbidity in patients with RA [2,6,7] due to the autoimmune disease 
itself [8] or immunosuppressive treatments [9,10]. The awareness of the 
possibility to prevent influenza infections and invasive pneumococcal 
disease by vaccination and the number of effectively performed 
vaccinations vary within the group of RA patients [6,11]. 
In view of these data highlighting the increased risk of 
infectious diseases in RA patients receiving immunomodulatory or 
immunosuppressive treatments on the one hand and differences in 
awareness and performance of vaccinations, e.g. against influenza 
or pneumococcal infections, on the other hand, the need for clear 
recommendations for vaccinations under use of biologic agents is 
demanding. However, data on immunogenicity, efficacy and safety of 
vaccinations in RA patients on immunotherapy are rare and difficult to 
compare due to heterogeneity in the disease course itself, in treatments, 
study designs and type of vaccines [12]. Thus, the review elucidates the 
aspects of immunogenicity, efficacy and safety with special focus on 
influenza and pneumococcal vaccination in RA patients treated with 
biologic agents following a systematic review of literature.
Methods
Primary information from published data in PubMed between 
January 1990 and December 2012 were considered for systematic 
review by using the search terms “abatacept”, “adalimumab”, 
“anakinra”, “certolizumab”, “etanercept”, “golimumab”, “infliximab”, 
“rituximab” or “tocilizumab” combined with Medical Subject 
Headings (MeSH terms) “rheumatoid arthritis” and “vaccination” 
limited to publications in English, to human studies and original 
studies. The recommendations of “Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses” (PRISMA) statement was 
applied to identify articles, to screen the abstracts for exclusion criteria 
(non-human studies, reviews, case reports, reports on secondary data) 
and to assess eligibility of full-text articles for inclusion of articles into 
qualitative data analysis and narrative reporting [13]. Reviews and 
reports on secondary data were excluded from evaluation, but cited in 
some cases when appropriate to provide additional literature on the 
topic. Case reports were used for illustration of single case experiences. 
Experiences with vaccinations in other autoimmune disorders (e. g. 
juvenile idiopathic arthritis, ankylosing arthritis, psoriatic arthritis) 
treated with immunotherapies were reported when being of interest 
for comparison with reports on RA or in cases of missing data for RA 
patients. 
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Research for abatacept revealed 8 articles, of them 2 articles were 
included into review, research for adalimumab 11 articles (including 
5), for etanercept 17 (including 7), for infliximab 22 (including 9), for 
rituximab 15 (including 6) and for tocilizumab 1 article (included). No 
articles were found for anakinra, certolizumab and golimumab. 
Results
Influenza and Pneumococcal vaccinations
Anti-TNF-α agents: TNF enhances antibody function and 
promotes B cell proliferation [14]. In view of these facts, it is of concern 
whether antibody responses may be impaired by anti-TNF-α agents, 
such as etanercept, adalimumab and infliximab, used in the treatment 
of RA.
Etanercept is a soluble TNF receptor that inactivates the function 
of TNF. Infliximab is a chimeric monoclonal antibody directed against 
TNF. Adalimumab is a human, monoclonal antibody against TNF and 
neutralizes the effects of TNF by inhibiting its interaction with TNF-
RI/II cell-surface receptors [15]. 
Influenza vaccination: Several studies on vaccination against 
influenza infection in RA patients considered anti-TNF-α agents, 
although the three approved anti-TNF-α drugs were not separately 
assessed in most studies. 
Some results exist from RA patients treated with adalimumab 
or placebo from approval studies. In a double-blind, randomized, 
multicenter study, patients received adalimumab or placebo on days 
1, 15 and 29 and were vaccinated with 23-valent pneumococcal and 
influenza vaccines on day 8 [16] (Table 1). Vaccine responses to 
pneumococcal antigens were similar in the adalimumab and the 
placebo group, as well as percentages of individuals with protective 
antibody titers [16]. Percentages of adalimumab treated patients 
achieving a vaccine response to influenza were generally lower than 
found in the placebo group [16]. This result was explained by the 
subgroup of patients with pre-existing protective antibody titers at 
baseline. For RA patients without protective antibody titers at baseline 
the percentages of responding adalimumab-treated patients and 
patients with protective antibody titers after vaccination were similar 
to the placebo group [16].
Some results exist also for infliximab compared to other treatments 
than anti-TNF-α agents. In a study comparing 20 RA patients with a 
mean dose of 3 mg/kg infliximab and 23 RA patients on DMARDs 
other than anti-TNF-α agents and 17 healthy controls, split-virion 
inactivated influenza vaccine (containing influenza A/H3N2, A/H1N1 
and influenza B) was administered on the day of administration of 
infliximab or 3 weeks after infliximab [17] (Table 1). In RA patients 
receiving the vaccine 3 weeks after administration of infliximab the 
increase of geometric mean titers (GMTs) was not significant for H1N1 
and H3N2. The percentage of responders were similar in all groups 
with no influence of age, gender, methotrexate or glucocorticoid use 
[17]. The disease activity remained unchanged in vaccinated patients 
[17]. In that study it was expected that the effect of infliximab would be 
maximal with the concomitant administration of the vaccine, however, 
the timing seemed not to influence the response to the influenza 
vaccine [17].
However, most studies did not distinguish between the different 
anti-TNF-α drugs approved for treatment of RA. In the past three 
years, many studies originated from the urgent demand to vaccinate 
RA patients during pandemic influenza.
In a study including 41 RA patients with all three anti-TNF-α 
agents and 41 RA patients on DMARDs alone, similar seroconversion 
rates were reported after non-adjuvanted, inactivated split-virion 
pandemic influenza A H1N1 vaccination compared to 117 healthy 
controls with a negative effect of methotrexate on the vaccine-specific 
response [18] (Table 1). Evaluating the immunogenicity of inactivated 
non-adjuvanted pandemic H1N1 vaccine among 258 RA patients 
with an unreported number of patients on anti-TNF-α therapy the 
proportions of seroprotection, seroconversion and GMT ratios post-
vaccination were similar to elderly persons ≥60 years of age [19] (Table 
1). Another study also presented data that anti-TNF-α agents did not 
severely diminish seroprotection rates [20] (Table 1). In addition, 
glucocorticoids did not seem to influence the immunogenicity of 
pandemic MF59-adjuvanted H1N1influenza vaccination in RA 
patients [20]. 
However, some other studies could not confirm the similar response 
to influenza vaccination in RA patients treated with anti-TNF-α agents 
compared to RA patients on DMARDs alone or to healthy individuals. 
In a study including 343 RA patients with an unreported number of 
anti-TNF-α treatment and a small proportion of rituximab use (0.8% 
in the whole group of 1668 patients with autoimmune rheumatic 
disease), a lower seroprotection rate against non-adjuvanted influenza 
A/H1N1 vaccine was reported compared to 234 healthy controls 
after immunization [21] (Table 1). Regardless of anti-TNF-α therapy 
(n=47) or not (n=293), lower GMTs, factor increase in GMTs and 
postvaccination seroprotection rates were found after adjuvant-free 
pandemic influenza A/H1N1 vaccination [22] (Table 1). However, 
methotrexate was the only DMARD associated with the reduced 
response [22]. Unlike to the other reported studies [18-20], disease 
activity did not influence the vaccine-specific responses [22]. 
Immunization against seasonal influenza infection is generally 
recommended in RA patients [23,24]. Vaccination with trivalent 
influenza vaccine (A/H1N1, A/H3N2, B) was performed in 50 RA 
patients treated with anti-TNF-α agents (etanercept or infliximab) in 
combination with methotrexate, 62 RA patients receiving anti-TNF-α 
agents alone or with other DMARDs than methotrexate and 37 RA 
patients treated only with methotrexate and 18 healthy controls [25] 
(Table 1). In that study, post-vaccination GMT increased significantly 
compared to pre-vaccination titers in all treatment groups and 
controls and also to each strain and percentages of responders were 
similar. The serological response was better in RA patients treated with 
methotrexate alone [25]. 
In another study, the percentage of responders to inactivated 
influenza vaccine was generally lower in 82 RA patients treated with 
various DMARDs (infliximab in 22 cases, etanercept in 5 cases) 
compared to 30 healthy controls, but was not affected by prednisone 
treatment or any DMARD, including methotrexate, infliximab and 
etanercept [26] (Table 1).
A study including a mixed group of 112 patients with different 
autoimmune diseases, containing 79 RA patients, demonstrated lower 
postvaccination GMTs against influenza antigens (A/H3N2 and B) 
in patients treated with anti-TNF-α agents compared to patients not 
on anti-TNF-α agents and healthy controls (n=18) [27] (Table 1). 
However, protection rates were not lower in the anti-TNF-α treated 
group [27]. 
A favorable outcome with protective antibody responses against 
influenza antigens at least 6 months after vaccination with non-
adjuvanted influenza vaccine over three consecutive influenza seasons 
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Ref. Study* design Population n anti-TNF-α 
therapy (n)
Patients on 
methotrexate (%)
Vaccines Effect in RA patients Lower 
responsei
[16] P, DB, R, PC, 
MC
RA
RA
99
109
a (99)
--- 
56.0
54.0
PPV
and TIV
PPV: Vaccine responsesa in adalimumab (37.4%) and placebo 
group (40.4%) and percentages of individuals with protective 
antibody titersb (adalimumab: 85.9%; placebo: 81.7%) similar
TIV: Percentages of responding RA patients on adalimumab 
(51.5%) lower than in the placebo group (63.3%)
RA patients without protective antibody titers at baseline: 
percentages of responding adalimumab-treated patients (73.3%) 
similar to the placebo group (73.9%), as well as percentages 
of individuals with protective antibody titers after vaccination 
(adalimumab: 98%; placebo: 94.5%)
No
Yes
No
No 
[17] C, SC RA
AS
HC
43
18
17
i (20)
i (18)
---
81.3
66.7
---
TIV RA patients vaccinated 3 weeks after administration of infliximab: 
increase of geometric mean titers (GMTs) was not significant for 
H1N1 and H3N2
Percentage of respondersc similar in all groups
Yes
No
[18] P, C, SC Anti-TNF-α 
(n=120): 
RA
AS
PsA
DMARDs alone 
(n=116):
RA
AS
PsA
HC
41
57
22
41
75
53
117
e (26)
a+i (94)
---
---
---
---
35.8
53.4
pIV Similar seroconversion ratesd compared to 117 healthy controls
Negative effect of methotrexate on the vaccine-specific response
No
[19] P, MC RA
JIA
HIV
Cancer
KTX
Elderly
258
83
255
319
85
149
n. r. n. r. pIV Proportions of seroprotection, seroconversiond and GMT ratios 
post-vaccination were 61.5%, 53.1% and 7.5 similar to elderly 
persons ≥ 60 years of age (63.1%, 55.7% and 5.7)
No
[20] C, SC RA
PsA
AS
SLE
HC
41
17
15
21
25
a/e/i (3/5/5)
(4/4/6)
(2/2/8)
---
---
61.0
41.2
6.7
14.3
---
pIV Significant increase of GMTs in RA patients (5.7 to 64.3) (HC: 
4.3 to 127)
Proportion of respondersc significantly lower in RA patients 
(56%) compared to HC (84%)
Seroprotection ratesd slightly lower in RA patients (71%) 
compared to HC (92%)
No
Yes
Yes
[21] P, C, SC RA
ORD
HC
343
1325
234
n. r.
n. r.
---
n. r. 
n. r.
---
pIV Factor increase of GMT in RA patients (7.2) lower than in HC 
(13.2)
Seroconversion rated in RA patients (53.4%) lower than in HC 
(76.9%) 
Seroprotection rated in RA patients (60.1%) lower than in HC 
(82.9%)
Yes
Yes
Yes
[22] P, C, SC RA
HC
340
234
a/e/i 
(16/11/20)
---
63.2
---
pIV Lower GMTs (71.9), factor increase in GMTs (9.6) and post-
vaccination seroprotection ratesd (67.4%) in RA versus HC 
(122.9, 13.2 and 82.9%, respectively)
Yes
[25] C, SC RA
HC
149
18
n. c. (112)
---
58.4
---
TIV Postvaccination GMT increased significantly compared to 
pre-vaccination titers in all treatment groups and controls
No
[26] C, SC RA
HC
82
30
i/e (22/5)
---
68.3
---
TIV Similar GMTs in RA compared to HC for all influenza antigens
Percentage of responders to B antigen lower in RA (67%) than 
in HC (87%)
No
Yes
[27] C, SC RA
ORD
79
33
RA+ORD: 
a/e/i 
(21/14/29)
RA+ORD: 71.0 TIV Lower postvaccination GMTs by anti-TNF-α treatment, 
without lowering protection rates
Yes
No
[28] C, SC RA
HC
28
10
n. c.
---
n. r.
---
TIV Similar response in seroconversion and seroprotection ratesd 
and in seroconversion factore
No
[30] R, PC, MC RA 70 i (56) 71.4 PPV Although 80% to 85% of patients in the treatment groups 
respondedf to at least one serotype, only 20% to 25% responded 
to ≥ 6 different serotypes
Yes
[31] C, SC RA
HC
149
47
e/i (48/64)
---
58.4
---
PPV Immunization responseg was similar between RA and HC against 
serotype 23F and 6B
No
[32] SC RA 31 e/i (12/4) 65.0 PPV Significant increase of GMTs to all 7 serotypes tested
Lower proportions of RA patients on anti-TNF-α therapy with a 
>2-fold increase (e. g. 23F: 13% versus 53% not treated with 
anti-TNF-α)
No
Yes
[34] MC RA
SpA
253
252
n. c. (168) RA+SpA: 68.8 PCV Antibody response ratioh was higher in RA patients receiving anti-
TNF-α alone (36.7%) compared to RA patients with methotrexate 
alone (21.2%) and anti-TNF-α and methotrexate (15.7%)
No
[35] C, MC RA†
RA
HC
253†
149
47
n. c.† (168)
n. c. (112)
---
68.8†
58.4
---
PCV† and 
PPV
Positive antibody response ratios and the positive antibody 
responseh were similar between the groups for the tested 
serotypes 23F and 6B
No
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was also reported in a study with 28 patients with low to moderate, 
stable RA on anti-TNF-α agents and confirmed vaccine safety [28] 
(Table 1). 
However, some experience from patients with inflammatory bowel 
disease who were vaccinated against influenza revealed a higher risk of 
an inadequate response to vaccination in those treated with infliximab 
and concomitant immunomodulatory therapy with glucocorticoids, 
6-mercaptopurine or methotrexate [29].
Overall, there is no consistent evidence of lower ability in mounting 
protective immune responses following influenza vaccination while 
being treated with anti-TNF-α therapy. Interestingly, according to 
the presented studies, different responses to the pandemic influenza 
vaccine compared to seasonal influenza vaccines were seen with 
no clear advantage of different vaccine preparations or adjuvanted 
formulations. 
Pneumococcal vaccination: Pneumococcal vaccination is strongly 
recommended in patients with chronic diseases and immunsuppressive 
treatments to prevent from invasive pneumococcal disease [23]. Studies 
exist on the immune response to antigens contained in the 23-valent 
polysaccharide vaccine and in the conjugated pneumococcal vaccine. 
Twenty RA patients who received infliximab 3 mg/kg plus 
methotrexate in the ASPIRE substudy, 36 RA patients who received 
infliximab 6 mg/kg plus methotrexate and 14 on placebo plus 
methotrexate were enrolled into a vaccination program administering 
23-valent polysaccharide pneumococcal vaccine at 34 weeks after 
initiation of infliximab [30] (Table 1). The antibody responses were 
assessed 4 weeks after vaccination using an enzyme immunoassay for 
reactivity to a panel of the 12 serotypes of the pneumococcal vaccine 
[30]. RA patients under 45 years of age and those on oral glucocorticoids 
generally appeared to respond better than those aged 45 to 65 years and 
without oral glucocorticoids [30]. 
In a study analyzing 62 RA patients on anti-TNF-α therapy 
(infliximab: 27; etanercept: 35) alone, 50 RA patients on anti-TNF-α 
therapy (infliximab: 37; etanercept: 13) with methotrexate, 37 RA 
patients with methotrexate alone and 47 healthy controls, a significant 
increase of antibody concentrations against serotypes 23F and 6B after 
23-valent pneumococcal vaccination was found in all groups [31] 
(Table 1). The highest response was found in RA patients treated with 
anti-TNF-α therapy without methotrexate, compared to those with 
concomitant methotrexate or methotrexate alone [31]. 
Comparing 16 RA patients on anti-TNF-α agents and 17 patients 
without anti-TNF-α agents, both groups had a significant increase 
of GMTs to all 7 serotypes tested after 23-valent polysaccharide 
pneumococcal vaccine [32] (Table 1). However, lower proportions of 
RA patients on anti-TNF-α therapy responded with a >2-fold increase 
[32].
Conjugate pneumococcal vaccines were supposed to induce a 
significant better T cell dependent response, particularly in children. 
Conjugate pneumococcal vaccination was successfully applied in 
children with juvenile idiopathic arthritis (JIA), but with less response 
against serotypes 4, 14 and 23F in those receiving anti-TNF-α agents 
[33] (Table 1). A ≥ 4-fold increase of baseline titers to ≥ 5 vaccine 
serotypes was found in 50% of JIA patients with anti-TNF-α agents 
plus DMARDs compared to 70% of JIA patients with DMARDs alone 
[33]. 
The use of conjugate pneumococcal vaccination was also investigated 
in adults with RA [34] and tested against plain polysaccharide vaccine 
[35] (Table 1). In study vaccinating 253 RA patients with different 
treatment regimens (85 receiving methotrexate alone, 89 anti-
TNF-α agents and methotrexate and 79 anti-TNF-α agents alone), a 
better antibody response ratio to a single dose of 7-valent conjugate 
pneumococcal vaccine was seen in RA patients without methotrexate 
treatment [34]. In that study, methotrexate was thought to negatively 
influence the T cell dependent response to conjugate vaccines [34]. 
Using a logistic regression model, higher age at vaccination and 
concomitant methotrexate were identified as predictors of an impaired 
positive antibody response for both serotypes, whereas the type of 
vaccine has no influence on these parameters [34]. Those RA patients 
vaccinated with the 7-valent conjugate vaccine [34] were compared to 
149 RA patients considering different treatment groups (methotrexate 
alone, anti-TNF-α agents and methotrexate and anti-TNF-α agents 
alone) and 47 healthy controls, both groups receiving a single dose 
of 23-valent polysaccharide vaccine [35]. Positive antibody response 
ratios and a positive antibody response were found to be similar 
between the groups for the tested serotypes 23F and 6B 4 to 6 weeks 
aA response to the vaccine was defined by a ≥ 2-fold titer increase from baseline at day 8 in ≥ 3 of 5 pneumococcal antigens and ≥ 4-fold increase from baseline in ≥ 2 of 
3 influenza antigens [16]
bProtective antibody titers were defined by pneumococcal antibody concentrations ≥ 1.6 µg/ml to ≥ 3 of 5 antigens and by influenza antibody titers ≥ 1:40 to ≥ 2 of 3 antigens 
at 4 weeks after vaccination [16]
cA response to the vaccine was defined by a ≥ 4-fold rise in hemagglutination inhibition (HI) antibodies 4 to 6 weeks after vaccination or seroconversion in patients with a 
non-protective baseline level of antibodies <1:40 [17]
dSeroprotection was defined by influenza antibody titers ≥1:40 and seroconversion by pre-vaccination titer <1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination 
titer ≥ 1:10 and a ≥ 4-fold increase postvaccination [18]
eThe seroconversion factor was calculated by the post-vaccination antibody titer divided by the pre-vaccination antibody titer and was considered as cut-off level of vaccine 
immunogenicity for adults 18-60 years when exceeding 2.5 (2.0 in people aged >60 years) [28]
fA response was defined if postvaccination antibody levels met the threshold value used by Quest Diagnostics (Van Nuys, CA) or if there was a ≥ 2-fold increase in pre- to 
postvaccination antibody levels in ≥ 6 of the 12 serotypes [30]
gThe immunization response was calculated as ratio of post- and prevaccination concentrations [31] 
hA positive antibody response was defined as the antibody response ratio (ratio of post- to prevaccination antibody levels) of ≥ 2 [34,35] 
iResponse of RA patients compared to the comparator in the study
†Identical with [34]
*Study design is given as described in the corresponding reference
Abbreviations
Ref: Reference; P: Prospective Study; DB: Double-Blind Study; C: Controlled Study; PC: Placebo-Controlled Study; R: Randomized Study; SC: Single-Center Study; 
MC: Multi-Center STUDy; RA: Rheumatoid Arthritis; SpA: Spondylopathic Arthritis; AS: Ankylosing Arthritis; PsA: Psoriatic Arthritis; HC: Healthy Controls; KTX: Kidney 
Transplantation; JIA: Juvenile Idiopathic Arthritis; HIV: Human Immunodeficiency Virus; SLE: Systemic Lupus Erythematosus; ORD: Other Rheumatic Diseases; n. r.: not 
reported; n. c.: not classified for different anti-TNF-α agents; DMARDs: Disease-Modifying Anti-Rheumatic Drugs; a: adalimumab; e: etanercept; i: infliximab; PPV: 23-valent 
Pneumococcal Polysaccharide Vaccine; PCV: 7-valent Pneumococcal Conjugated Vaccine; TIV: Trivalent Influenza Vaccine; pIV: pandemic H1N1 influenza vaccine; GMT: 
Geometric Mean Titer 
Table 1: Effect of anti-TNF-α therapy in rheumatoid arthritis patients on antibody responses to vaccinations.
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after vaccination in all groups regardless of the type of vaccination [35]. 
Some experience also exists for inflammatory bowel disease with 
infliximab and 23-valent pneumococcal vaccination, demonstrating a 
significantly lower response rate in patients administered infliximab or 
combination immunsuppressive therapy (e.g. azathioprine) compared 
to the group only on mesalamine [36]. 
 Abatacept
Abatacept, a CTLA4-immunoglobuline-fusion protein, inhibits 
T cell activation by binding to CD80 and CD86, thus, blocking the 
interaction with CD28. This effect results in modulation of the CD80/
CD86:CD28 co-stimulatory signal which is required for full T cell 
activation. It has been approved for the treatment of RA in combination 
with methotrexate in a number of countries including the United 
States, Canada and the European Union. 
In 1,955 patients treated with abatacept during the double-blind 
periods of the approval studies, and 2,688 during the cumulative double-
blind and open-label periods, also aspects of immunogenicity, safety 
and efficacy of vaccines were studied showed a not markedly impaired 
response to tetanus toxoid and 23-valent pneumococcal vaccinations 
in healthy volunteers [37] and RA patients [38,39]. Antibody titers 
against non-adjuvanted monovalent pandemic 2009 influenza A/H1N1 
vaccine were evaluated by hemagglutination inhibition (HI) assay in 
11 RA patients treated with abatacept and concomitant non-biologic 
DMARDs compared to 33 age-matched RA patients on methotrexate 
and 55 healthy controls 21 days after vaccination [40]. Seroprotection 
(antibody titers ≥ 1:40) was significantly reduced in the abatacept-
treated RA patients (9%) compared to RA patients on methotrexate 
(58%) and healthy controls (69%) [40]. The factor increase in GMTs 
was lower in abatacept-treated RA patients (1.8) compared to the 
methotrexate-treated RA patients (8.7) and healthy controls (11.5) 
[40].
Rituximab
Rituximab is a monoclonal antibody against CD20, which 
diminishes the number of circulating B cells for a period of 6 to 9 
months after administration but does not affect circulating plasma cells 
or immunoglobulin levels. It is approved by American and European 
authorities for the treatment of RA patients in whom anti-TNF-α 
therapy failed [41]. 
The reports on the humoral immune response to influenza 
vaccination in RA patients treated with rituximab are conflicting. 
Significantly lower HI titers after trivalent influenza vaccination 
(influenza A/H3N2, A/H1N1 and influenza B) were observed in 4 
RA patients on rituximab with a median B cell count <10×106 cells/l 
compared to 19 RA patients on etanercept with or without DMARDs 
and 20 healthy controls [41]. 
In a study comparing 14 rituximab-treated RA patients, 29 RA 
patients treated with other DMARDs and 21 healthy controls vaccinated 
with a split-virion inactivated influenza A/H3N2 (California), A/
H1N1 (New Caledonia) and influenza B (Shanghai) vaccine, a lower 
proportion of responders to the California antigen was found in the 
rituximab-treated group (21% responders versus 67% in the non-
rituximab groups) [42]. In that study, a sufficient immune response 
was defined by an at least fourfold rise in HI titers 4 weeks after 
vaccination in patients with baseline titers ≥ 1:40 or a rise of HI titers 
≥ 1:40 in patients with non-protective pre-vaccination titers <1:40. A 
response to more than one antigen was found in 14% of rituximab-
treated RA patients, but in 48% of the non-rituximab patients and 40% 
of healthy controls [42]. The authors found no correlation between 
influenza vaccination and activity parameters, such as swollen and 
tender joint counts, duration of morning stiffness, level of pain, 
erythrocyte sedimentation rate or C-reactive protein levels, the use 
of glucocorticoids or methotrexate or frequency of CD19+ B cells or 
time interval since receiving rituximab [42]. Higher proportions of 
responders to the California antigen were seen in patients treated with 
lower numbers of various DMARDs [42].
In another study, trivalent influenza vaccine (influenza A/H3N2, 
A/H1N1 and influenza B) was administered to 11 RA patients 4 to 8 
weeks after rituximab (early rituximab subgroup) and to 12 RA patients 
6 to 10 months after rituximab (late rituximab subgroup), which were 
compared to 20 RA patients receiving methotrexate and 29 healthy 
controls [43]. No increase of antibody titers against any vaccinated 
influenza strain was found in the early rituximab subgroup. Some 
recovery of the humoral immune response was seen in the late rituximab 
subgroup, with a significant increase of GMTs after vaccination for the 
A/H3N2 and the A/H1N1 strain [43]. Seroconversion was seen only 
in 3 patients of the late rituximab subgroup against the A/H1N1 strain 
[43]. Only 6 cases of seroprotection occurred in the rituximab group, 
of them 5 in the late rituximab subgroup. No correlation was seen 
between B cell counts and response to influenza vaccination [43].
Influenza-vaccine specific cellular responses were evaluated in 
RA patients at day 6 after vaccination who had rituximab treatment 
6 months ago (post-rituximab group) and in RA patients 6 days 
before rituximab administration (pre-rituximab group) compared to 
an RA patient control group, who was not exposed to rituximab [44]. 
Influenza-specific IgM-secreting B cells were significantly reduced in 
the post-rituximab group compared to the pre-rituximab group and to 
the control group [44]. Irrespective of rituximab treatment, the number 
of influenza-specific IgG- and IgA-producing cells was similar between 
the groups [44]. No difference was also seen in the vaccine-specific IgM 
increase between day 0 and 21 after vaccination [44]. 
Analyzing the cellular and humoral immune response to trivalent 
influenza subunit vaccine in 29 RA patients treated with rituximab, 
17 with DMARDs, mostly methotrexate, and 16 healthy controls, the 
Interferon-gamma-production by CD4+CD69+ T cells was similar, 
but the rituximab-treated RA group showed significantly diminished 
HI responses (26.4%) compared to the DMARD-treated RA group 
(68.4%) and healthy controls (47.1%) [45]. That study supported the 
finding, that an intact T cellular immune response is present in patients 
treated with rituximab [45].
However, there was a significant lower GMT response to adjuvanted 
H1N1 influenza vaccination in 5 RA patients with rituximab and 10 
RA patients with abatacept compared to 40 healthy controls [46]. Only 
25% of patients on rituximab showed a HI ≥ 1:40 at 3 weeks, 6 weeks 
and 6 months after vaccination, but 45%, 35% and 20% of patients with 
abatacept and 98%, 95% and 75% in healthy controls [46]. In that study 
a significant influence of disease type, intensity, type of medication and 
age were described [46].
In view of that data, several explanations were given to describe 
the discrepancy between studies showing lower responses to influenza 
vaccine antigens and almost normal responses under treatment of RA 
patients with rituximab. A decreased response in some rituximab-
treated RA patients to new antigens may be attributed to reduced 
amounts of B cells or to an increase of regulatory T cells suppressing 
the immune response [47]. A slower or delayed repopulation of CD27+ 
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memory B cells was described for more than 2 years after rituximab 
treatment [47]. The sufficient response to influenza vaccination in 
some rituximab-treated RA patients may be explained by early-
differentiated B cells with low-level expression of CD20, which may 
become the source of antibody production [48]. Despite the complete 
depletion of B cells in RA patients treated with rituximab, levels of 
immunoglobulins and pre-existing antibodies against tetanus and 
pneumococcal-polysaccharide remained stable, which was attributed 
to the existence of long-lived plasma cells [49]. An explanation for a 
missing correlation between peripheral B cell numbers and immune 
response to influenza vaccine [43] may be that the number of B cells 
within the lymphoid tissue is not correctly reflected by peripheral blood 
B cell numbers, as despite two cycles of rituximab, CD19+CD20- B cells 
are able to remain in the bone marrow in RA patients [50]. Higher 
post-vaccination titers in rituximab-treated patients which had higher 
pre-vaccination titers, point to the persistence of memory B cells in 
compartments other than the peripheral blood [24]. Probably, repeated 
vaccination can be of additional value in these patients to induce better 
immune responses [24]. 
Regarding safety aspects, none of the studies [41-46] showed a 
significant increase of flares, inflammatory parameters or worsening 
of the disease.
Tocilizumab
IL-6 has been shown to work as a B cell differentiation factor, which 
promotes activated B cells to produce immunoglobulin [51]. Blocking 
IL-6 should therefore impair antibody production. Tocilizumab is a 
humanized monoclonal anti-IL-6 receptor antibody which has been 
shown to be effective in RA patients with moderate to severe RA who 
have demonstrated an insufficient response to methotrexate and one 
or more anti-TNF-α agents [52]. Little experience with vaccinations 
under treatment with tocilizumab exists from studies in children and 
young adults with systemic JIA.
Studies of 27 patients with systemic JIA showed a similar efficacy 
4 to 7 weeks after influenza vaccination with no influence of duration 
of tocilizumab therapy compared to 17 healthy controls [53]. In that 
study, no severe adverse events or disease exacerbation was recorded 
after the influenza vaccination [53]. However, one case of disease 
exacerbation after influenza vaccination was reported in a single 
patient with systemic JIA receiving tocilizumab [54]. 
Assessing the impact of tocilizumab therapy on the HI antibody 
response to influenza vaccination for the A/H1N1 and A/H3N2 strains 
in patients with RA, both groups, the group treated with tocilizumab 
alone (n=62) and the group treated with tocilizumab and methotrexate 
(n=49) reached postvacccination seroresponse rates (seroconversion 
or ≥ 4-fold increases in antibody titers whose pre-vaccination titers 
were ≥ 1:10) greater than 40% and seroprotection rates (antibody titers 
≥ 1:40) greater than 70% [55]. Methotrexate alone seemed to have a 
negative impact on GMTs, although protection responses were not 
different from the other groups [55]. 
Explanations for almost normal immune responses to vaccinations 
under tocilizumab may be, that IL-6 is not the sole factor participating 
in antibody production by B cells and that IL-6 signaling may not 
completely inhibited in lymphoid tissues, which allows to ongoing 
antibody production to specific antigens. 
Other vaccinations
Despite significantly increased risks of infectious complications of 
vaccine-preventable diseases, experiences with other vaccinations than 
influenza and pneumococcal vaccines are rare in RA patients receiving 
immunotherapies.
In a controlled study, 64 RA patients on rituximab and methotrexate 
were compared to 26 RA patients on methotrexate alone regarding 
their response to tetanus toxoid vaccination [56]. Both groups showed 
similar titer increases, similar numbers of patients with non-protective 
titers and no differences in GMTs prior to vaccination and 4 weeks 
after vaccination [53].
Regarding hepatitis A and B vaccination, efficacy and safety was 
demonstrated in children with JIA [57] and RA patients on methotrexate 
and other conventional DMARDs [58], but no data exist from RA 
patients receiving immunotherapies. Although human papillomavirus 
vaccination should be considered in young women with RA, no 
experience with human papillomavirus vaccination was reported in 
RA patients. Similarly, no data exist for cholera, diphtheria, pertussis, 
meningococcal, poliomyelitis, rabies and tick-borne encephalitis 
vaccinations in RA patients. RA patients on immunotherapies 
planning to travel abroad should receive their vaccinations according 
to general rules, except for live-attenuated vaccines, such as Bacillus 
Calmette-Guérin (BCG), oral poliomyelitis, oral typhoid fever and 
yellow fever vaccines, due to expected life-threatening dissemination 
of the attenuated pathogens [23].
Among RA patients an increased risk of herpes zoster was 
described [59,60]. A large prospective cohort study investigated 
the long-term safety and effectiveness of anti-TNF-α therapy in 
the treatment of 3,266 RA patients (adalimumab 1,423 patients, 
etanercept 1,252 patients, infliximab 591 patients) compared to 1,774 
RA patients on conventional DMARDs [59]. A significantly higher 
incidence rate of herpes zoster was observed in RA patients receiving 
infliximab/adalimumab (11.1 per 1,000 patient-years) or etanercept 
(8.9) compared to RA patients on conventional DMARDs (5.6) [59]. 
A significant reduction of postherpetic neuralgia was demonstrated in 
older adults vaccinated with a high-antigen containing live-attenuated 
herpes zoster vaccine [61]. However, poor experience with the herpes 
zoster vaccine exists for RA patients in unease of severe adverse effects 
and dissemination of the vaccine-type varicella-zoster virus. Based on 
expert opinions, glucocorticoids at prednisone-equivalent doses up to 
20 mg/day, low doses of methotrexate (<0.4 mg/kg/week), azathioprine 
(<3.0 mg/kg/day) and 6-mercaptopurine (<1.5 mg/kg/day) were 
considered to be safe and do not define a contraindication against 
herpes zoster vaccination [62], but the vaccine is not recommended 
for RA patients with biologic treatments [24]. In a large cohort study 
among 44,115 patients with autoimmune diseases aged ≥ 50 years, 551 
patients received the herpes zoster vaccine, of them 32 patients were 
treated with anti-TNF-α therapy at the time of vaccination and 47 
patients used biologics at some time within 30 days before and after 
vaccination [62]. None of these patients developed herpes zoster in the 
30 days after vaccination [62]. 
Regarding the general problem with live-attenuated vaccines in 
immunocompromised patients, studies of children with autoimmune 
rheumatic diseases on methotrexate, low dose glucocorticoids or anti-
TNF-α therapy receiving immunological booster with live-attenuated 
measles, mumps, rubella or varicella vaccination reported no severe 
adverse events [63,64].
Discussion
However, researchers, rheumatologists and physicians taking care 
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of patients with RA on immunotherapies are faced with several problems 
regarding vaccination studies and deduction of recommendations 
(Table 2). An EULAR expert committee used a Delphi voting system for 
addressing 8 key questions and 13 recommendations for vaccinations 
in patients with autoimmune inflammatory rheumatic diseases 
[23]. In the initial work-up of patients, particularly before starting 
immunsuppressive or immunomodulatory therapies, the vaccination 
status should be assessed [23]. Ideally, vaccines should be administered 
during stable disease [23]. Vaccinations can be administered during 
the use of DMARDs and immunotherapies [23]. However, awareness 
should be given to the type of vaccine used (e.g. adjuvanted or non-
adjuvanted, conjugated or polysaccharide, non-live-attenuated or live-
attenuated vaccines) and a delayed, lower or faster declining immune 
response has to be considered. 
Particularly, the administration of live-attenuated vaccines displays 
a challenge in potentially immunsuppressed patients. Herpes zoster 
vaccination is a promising strategy to avoid herpes zoster associated 
complications, such as postherpetic neuralgia [61], and may be 
considered in cases of low to moderate immunosuppression according 
to the Advisory Committee on Immunization Practices (ACIP) [65]. 
Inactivated influenza and 23-valent polysaccharide pneumococcal 
vaccinations are strongly recommended for patients with autoimmune 
inflammatory rheumatic diseases. Data regarding efficacy and 
immunogenicity of influenza and pneumococcal vaccines in patients 
with RA receiving immunotherapy with anti-TNF-α agents, blockade 
of the CD80/CD86:CD28 co-stimulatory signal or of IL-6 or depletion 
of B cells are rare and often conflicting. Crucial problems in the 
interpretation of data from studies in RA patients vaccinated against 
influenza and pneumococcal disease are the impaired comparability of 
studies due to different study designs and type of vaccines used, different 
health states among RA patients, heterogeneity in treatments including 
concomitant therapy with conventional DMARDs and glucocorticoids 
in addition to biological agents. Particularly in studies from the past, 
there is a selection of cases which may suffer from a more severe disease 
where several conventional DMARDs failed and new approaches with 
biologic agents are undertaken. But there may be also a change over time 
in prescription habits and a more courageous use of immunotherapies 
in patients in whom the first DMARD (usually methotrexate) was not 
successful to induce remission. Different study designs with different 
time points of antibody evaluation and different study end points (e.g. 
GMTs, the relative increase of antibody titers, protective antibody titers) 
do not allow to compare the studies to each other. Further problems are 
small numbers of RA patients studied and often the inclusion of various 
biologic agents with or without conventional DMARDs into one 
group compared to different control groups, consisting of randomly 
taken healthy individuals or RA patients on conventional DMARDs 
with or without methotrexate or glucocorticoids on different dosages. 
However, no trend to lower vaccine responses could be deduced from 
studies including larger numbers of patients (Table 1). Also, in most 
studies the time on immunotherapies and the timing of vaccination is 
not considered in the interpretation of results. Conflicting data were 
presented for influenza vaccination, showing an influence of timing 
regarding treatment of rituximab [43,44] or not [42]. Prevaccination 
antibody titers may also influence the results [16]. 
An extrapolation of immune responses from one influenza vaccine 
to another may be not permitted, as so far no clear benefit of adjuvanted 
or non-adjuvanted influenza vaccines or different antigen preparations 
could be deduced from studies.
Study aspects Individual aspects Laboratory aspects
• Study design (cross-sectional, cohort studies; placebo controlled, 
randomized, double-blind; prospective or retrospective; investigational 
or non-investigational, observational studies)
• Inclusion and exclusion criteria
• End points (GMTs, increase of titers, protective titers)
• Heterogeneity of compared groups (healthy controls or RA patients)
• Heterogeneity in vaccine preparations (adjuvanted or non-
adjuvanted; polysaccharide or conjugated; containing antigens)
• Timing of vaccination
• Health state
• Disease course
• Severity of disease
• Co-morbidities
• Age 
• Gender and hormonal changes
• Life-style factors (e. g. smoking, alcohol)
• Heterogeneity in use of immunotherapies
• Duration of immunotherapies
• Heterogeneity in use of conventional DMARDs and 
glucocorticoids
• Time point of antibody assessment
• Pre-vaccination titers
• Assays used (sensitivity and specificity)
• Specificity of antigens used in assays
• Definition of response and protection
Table 2: Influencing factors for interpretation of immunogenicity and efficacy in vaccine studies in RA patients on immunotherapies.
Age remains an important confounder in vaccine studies, as lower, 
delayed or faster decreasing humoral immune responses are reported 
in elderly, healthy individuals [66]. Influence of age on responses to 
the pneumococcal vaccine was also seen in RA patients treated with 
infliximab and glucocorticoids [30]. Aspects of immunological aging 
[66] are mostly not considered in the evaluation of antibody titers and 
antibody maintenance in RA patients on immunotherapy. 
A study in ovarectomized mice showing lower antibody levels to 
influenza vaccine than mice receiving estradiol suggested an influence 
of gender and hormone status on the specific immune responses [67]. 
Interestingly, hormonal aspects were mostly covered by factors of 
disease activity as shown in a study of hormone replacement therapy 
in women with RA [68]. Hormonal replacement therapy was not 
associated with an altered response to influenza vaccination [68]. 
Also, the effect of lifestyle factors, such as alcohol consumption 
and smoking, on the immune response should be considered when 
conducting vaccination studies. Smoking has been shown to be a 
predictor of an impaired immune response to pneumococcal conjugate 
vaccine antigens 23F and 6B in RA patients on methotrexate [69].
Additionally, assays used to assess the antibody response differ 
between the studies and protective antibody titers described for healthy 
volunteers may not necessarily correlate with protection in RA patients. 
It remains widely unclear how long protective antibody titers exist in 
patients with RA and no recommendations are collated for antibody 
titer controls and booster intervals. 
An increase of vaccine-related adverse events did not appear 
in studies considering safety aspects of vaccines in RA patients on 
immunotherapies compared to RA patients on DMARDs alone. 
Unfortunately, these studies are generally underpowered to study 
adverse events as a primary outcome and therefore not conclusive 
[23,24].
Conclusion
Patients with RA are at higher risk to suffer from morbidity due 
to vaccine-preventable diseases and, thus, display an important 
target population to receive vaccines for protection from infectious 
complications. There have been only a few studies focusing on the 
administration of vaccines in RA patients with immunotherapy. 
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